US 2024/0174741 A1Published application

Il-38-specific antibodies

AssigneeImmunome, Inc.

InventorsMatthew K. ROBINSON, Karen LUNDGREN, Ben HARMAN, Pavel A. NIKITIN, Fang SHEN

Life of this patent

Estimating the term…

Abstract

This invention relates to antibodies specific for human interleukin-38 (IL-38), including isolated antibodies, or antigen-binding fragments thereof. The antibodies, or antigen-binding fragments thereof, described herm partially or fully block, inhibit, or neutralize a biological activity of IL 38. Methods described herm relate to inhibiting tumor growth or metastasis in an individual afflicted by tumor growth and/or metastasis.

Claims37

Dependent claims

A method of treating cancer in an individual comprising administering to the individual an antibody that binds to IL-38, wherein the antibody comprises

a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:22 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:57;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:98 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:101;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:7 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:10;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:87 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:92;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:27 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:57;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:37 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:67;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:42 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:72;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:47 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:77;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:32 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:62;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:52 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:82;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:2 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:4;

8 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/284,527Filed 28 Mar 2022
Priority: 28 Mar 2021
Published: 30 May 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification17 codes

C07K 16/244
Against cytokines, lymphokines or interferons: interleukins [IL]
A61P 35/00
Antineoplastic agents
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
A61K 2039/54
Medicinal preparations containing antigens or antibodies: characterised by the route of administration

Family

Application63/167,105Us provisional application · filed 28 Mar 2021
Application63/236,454Us provisional application · filed 24 Aug 2021
US 2024/0174741 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

A method of treating cancer in an individual comprising administering to the individual an antibody that binds to IL-38, wherein the antibody comprises

a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:22 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:57;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:98 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:101;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:7 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:10;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:87 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:92;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:27 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:57;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:37 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:67;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:42 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:72;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:47 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:77;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:32 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:62;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:52 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:82;
a VH CDR1, a VH CDR2 and a VH CDR3 of a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:2 and a VL CDR1, VL CDR2 and a VL CDR3 of a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:4;

8 more elements

Facts

Application

18/284,527Filed 28 Mar 2022

Priority

28 Mar 2021

Published

30 May 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification17 codes

C07K 16/244
Against cytokines, lymphokines or interferons: interleukins [IL]
A61P 35/00
Antineoplastic agents
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
A61K 2039/54
Medicinal preparations containing antigens or antibodies: characterised by the route of administration